×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALRN – aileron therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
07:07 am
alrn
Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]
High
Report
Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]
11/14
04:21 pm
alrn
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
High
Report
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/14
04:15 pm
alrn
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
High
Report
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/13
01:26 pm
alrn
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]
Low
Report
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]
11/13
07:00 am
alrn
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Medium
Report
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
10/31
07:30 am
alrn
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Medium
Report
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
10/12
09:00 am
alrn
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Low
Report
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/9
04:09 pm
alrn
Form 4 Aileron Therapeutics, For: Dec 05 Filed by: WINDSOR JAMES BRIAN
Low
Report
Form 4 Aileron Therapeutics, For: Dec 05 Filed by: WINDSOR JAMES BRIAN
12/6
04:41 pm
alrn
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Aivado Manuel
Medium
Report
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Aivado Manuel
12/6
04:38 pm
alrn
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Ambros Reinhard J.
Medium
Report
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Ambros Reinhard J.
12/6
04:35 pm
alrn
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Fairey William
Medium
Report
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Fairey William
12/6
04:35 pm
alrn
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: VON RICKENBACH JOSEF H
Medium
Report
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: VON RICKENBACH JOSEF H
12/6
04:33 pm
alrn
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Musso Alan A
Medium
Report
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: Musso Alan A
12/4
04:05 pm
alrn
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: WINDSOR JAMES BRIAN
Low
Report
Form 4 Aileron Therapeutics, For: Dec 02 Filed by: WINDSOR JAMES BRIAN
11/14
04:10 pm
alrn
Form 8-K Aileron Therapeutics, For: Nov 14
High
Report
Form 8-K Aileron Therapeutics, For: Nov 14
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/9
Aileron Therapeutics Inc (NASDAQ: ALRN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
14.8%
2/4 Form 4 AILERON THERAPEUTICS For: Jan 31 Filed by: Annis Allen 10.1%
7/17 Form EFFECT AILERON THERAPEUTICS 10.0%
9/5 Form 4 AILERON THERAPEUTICS For: Sep 04 Filed by: VON RICKENBACH JOSEF H 9.3%
9/3 Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York 7.9%
8/20 Form 4 AILERON THERAPEUTICS For: Aug 16 Filed by: Vukovic Vojo 6.8%
4/13 Form SC 13D/A AILERON THERAPEUTICS Filed by: Novartis Bioventures Ltd 6.3%
9/16 Form 4 AILERON THERAPEUTICS For: Sep 12 Filed by: VON RICKENBACH JOSEF H 6.1%
12/18 Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer 5.8%
9/11 Aileron Therapeutics Inc (NASDAQ: ALRN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock. 4.9%
2/4 Form 4 AILERON THERAPEUTICS For: Jan 31 Filed by: Annis Allen 10.1%
7/17 Form EFFECT AILERON THERAPEUTICS 10.0%
9/5 Form 4 AILERON THERAPEUTICS For: Sep 04 Filed by: VON RICKENBACH JOSEF H 9.3%
9/3 Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York 7.9%
8/20 Form 4 AILERON THERAPEUTICS For: Aug 16 Filed by: Vukovic Vojo 6.8%
4/13 Form SC 13D/A AILERON THERAPEUTICS Filed by: Novartis Bioventures Ltd 6.3%
9/16 Form 4 AILERON THERAPEUTICS For: Sep 12 Filed by: VON RICKENBACH JOSEF H 6.1%
12/18 Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer 5.8%
9/11 Aileron Therapeutics Inc (NASDAQ: ALRN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock. 4.9%
TOP News Decliners
9/30
Form 8-K AILERON THERAPEUTICS For: Sep 28
-25.5%
4/16 Form PRE 14A AILERON THERAPEUTICS For: Jun 17 -19.9%
9/28 Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology -19.1%
3/18 Form SC 13D/A AILERON THERAPEUTICS Filed by: Novartis Bioventures Ltd -17.5%
5/8 Q1/2019 3/31/2019 EPS -0.490 ZacksConsensus -0.360 ActVsEst (0.130) - Miss -13.3%
6/27 Thinking about buying stock in Aileron Therapeutics, Atossa Genetics, NVIDIA, Seelos Therapeutics, or Xpresspa? -12.2%
10/29 Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference -11.5%
3/30 Q4/2019 12/31/2019 EPS -0.260 ZacksConsensus N/A ActVsEst N/A - N/A -10.6%
11/8 Form SC 13G/A AILERON THERAPEUTICS Filed by: JENNISON ASSOCIATES LLC -9.6%
4/16 Form SC 13D/A AILERON THERAPEUTICS Filed by: Novartis Bioventures Ltd -9.4%
4/16 Form PRE 14A AILERON THERAPEUTICS For: Jun 17 -19.9%
9/28 Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology -19.1%
3/18 Form SC 13D/A AILERON THERAPEUTICS Filed by: Novartis Bioventures Ltd -17.5%
5/8 Q1/2019 3/31/2019 EPS -0.490 ZacksConsensus -0.360 ActVsEst (0.130) - Miss -13.3%
6/27 Thinking about buying stock in Aileron Therapeutics, Atossa Genetics, NVIDIA, Seelos Therapeutics, or Xpresspa? -12.2%
10/29 Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference -11.5%
3/30 Q4/2019 12/31/2019 EPS -0.260 ZacksConsensus N/A ActVsEst N/A - N/A -10.6%
11/8 Form SC 13G/A AILERON THERAPEUTICS Filed by: JENNISON ASSOCIATES LLC -9.6%
4/16 Form SC 13D/A AILERON THERAPEUTICS Filed by: Novartis Bioventures Ltd -9.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: